OncoMatch/Mesothelioma/BAP1 loss
MesotheliomaBAP1 loss Clinical Trials
2 recruiting trials·Updated daily from ClinicalTrials.gov
BAP1 inactivation occurs in approximately 60% of malignant pleural mesothelioma and impairs the deubiquitinase complex involved in DNA damage response and chromatin regulation. BAP1 loss is associated with better prognosis in some studies and may predict sensitivity to EZH2 inhibition through synthetic lethality. Trials investigate EZH2 inhibitors (tazemetostat) in BAP1-deficient mesothelioma, PARP inhibitor combinations exploiting BAP1-mediated HRD, and immunotherapy in BAP1-altered disease.
Top recruiting
Top recruiting BAP1 loss Mesothelioma trials
Ranked by phase and US site count. See all 2 trials matched to your profile →